Introduction {#Sec1}
============

Between 3 and 4% of the general population suffer from chronic daily headache (CDH) and a quarter to a third of them suffer from medication overuse headache (MOH) (\[[@CR1]--[@CR4]\], see specific European data in \[[@CR5]\]).

Psychopathological correlates of CDH have been assessed by various means: personality tests, diagnostic devices, and psychopathologic scales (see reviews in \[[@CR6]--[@CR8]\]). An approach with MMPI \[[@CR9]\] reveals a higher number of high scores (over 65) in chronic migraine and analgesic rebound headache patients when compared to episodic migraineurs. The prevalence of psychiatric disorders is high in CDH, mostly in anxiety and mood disorders \[[@CR10]--[@CR12]\]. The use of rating scales confirms this important psychopathological burden in CDH \[[@CR12]\] which was reported to be higher in patients with medication overuse \[[@CR13], [@CR14]\] who can be considered drug-dependent according to the DSM-IV definition \[[@CR15]\].

When assessed by various scales, the quality of life in CDH is reduced \[[@CR12], [@CR16]--[@CR19]\], particularly in transformed migraine patients \[[@CR17]--[@CR20]\]. However, these data are difficult to be transposed into the more recent actual international classification of headache disorders (ICHD) \[[@CR21]\] which was completed by the complementary note of the Headache Classification Committee \[[@CR22]\]. However, more studies based on accepted classifications (ICDH-2 and DSM-IV R) are needed \[[@CR23]\]. Furthermore, recent suggestions have been made to break out the medication overuse headache group (code 8.2) \[[@CR24], [@CR25]\].

In this study, we address the following question: in the entire group of patients who have CDH, do patients with migraine symptoms have a different psychopathology and quality of life burden than those with tension-type headache? Our analysis studies three well-defined groups of chronic headache: chronic migraine (CM, code 1.5.1), chronic tension-type headache (CTTH, code 2.3.2), and medication overuse headache (MOH, code 8.2). In the last group, using a special clinical analysis, we divided the patients into two subsets, those with migraine symptoms (mMOH) and those with tension-type symptoms (ttMOH).

Method {#Sec2}
======

This study was planned during the year 2000 and patients were enrolled between September 2001 and July 2002. We used the CTTH definition of ICHD-II and the proposals of the Headache Classification Committee (2006) for chronic migraine (CM) and MOH \[[@CR22], [@CR23]\]. Patients who had symptomatic headache and trigeminal-autonomic cephalalgia were excluded.

Population and sub-groups {#Sec3}
-------------------------

### Headache classification {#Sec4}

We enrolled 106 patients (75 females and 31 males) with a mean age of 47 years (range 17--83 years, mean 46.9 ± 15.5) who had consulted a neurologist, either in a liberal office (5 investigators), or in an outward consultation in an University Hospital (5 investigators),in the West of France (West Migraine Study Group) for chronic headache, i.e. headache occurring more than 15 days/month for more than 3 months, with attacks lasting more than 4 h when untreated \[[@CR5]\]. All patients gave prior, informed consent as recommended by the Tours University Hospital ethical committee. Two pre-inclusion investigator rating sessions were organised in order to homogenise the evaluations.

Each participating physician filled out a questionnaire which took into account the characteristics of the headache(s) reported by the patients. An algorithm automatically determined the classification of the headache. Thus, a given patient could theoretically report several types of headache and a given headache could receive several different ICHD-II codes. Headache which met criteria for both probable migraine (PM) (ICHD-II, code 1.6.1) and tension-type headache (TTH) was classified as TTH according to rule \# 5 of the ICHD-II. In each patient, we computed the number of days per month he or she suffered for each type of headache and specified the medications taken during the last 3 months; when necessary medical files were used to determine if patients filled ICHD-II criteria for MOH. The final classification identified 80 MOH patients, 8 chronic migraine (CM) patients, and 18 CTTH patients.

For the needs of the study, MOH patients were divided into two sub-groups: mMOH and ttMOH.mMOH, if they also fulfilled the criteria for chronic migraine (i.e. precisely, code 1.5.1 criteria A, B, and C according to the Headache Classification Committee (2006)) with the exception of drug abuse. We included patients into this subset who fit the diagnostic of probable migraine, in other words, code 1.1 criteria B or D (IHS classification 2004).ttMOH, if they fulfilled the diagnostic criteria for chronic tension-type headache (i.e. code 2.3 A--D criteria, IHS classification 2004) with the exception of the drug abuse.

Using this procedure, among the 80 MOH patients enrolled in the study cohort, 43 were classified in the mMOH group and 37 into the ttMOH group. It should be noted that four patients had mMOH between 8 and 15 days per month in addition to 15 days or more with ttMOH headache and were consequently classified in the mMOH group by analogy with the Headache Classification Committee (2006) position concerning chronic migraine criteria (code 1.5.1). Furthermore, one patient had mMOH for 5 days and headache with ttMOH characteristics for 12 days and was classified as ttMOH.

### Description of the sub-groups {#Sec5}

The demographic characteristics of the four sub-groups included the number of patients in each group, their ages, body mass index, the age at which they left school, marital status, and known previous psychiatric disorders and are summarised in Table [1](#Tab1){ref-type="table"}.Table 1Description of our sub-groupsNumber of patientsSub group 1\
Chronic migraineSub group 2\
Medication overuse headache: migraine typeSub group 3\
Chronic tension type headacheSub group 4\
Medication overuse headache: tension type8431837Age (years)46.5 (17.2)44.0 (15.2)47.3 (19.4)50.3 (13.1)Female/male8/033/1012/624/13Body mass index23.1 (3.4)18.6 (4.6)22.8 (3.2)23.9 (4.8)Life event impact Amiel Lebigre score477.5 (288.6)362 (478.7)243.3 (309)203.9 (238.7)Pain intensity index52.0 (12.3)61.8 (22.3)40.7 (15.8)47.4 (16.3)Age left school (years)18.4 (3.4)18.7 (3.9)16.8 (2.6)19.0 (5.8)Reported psychiatric disorders (number of cases)Depression (1)Depression (9), phobia (1)Depression (2), sexual abuse (1)Depression (6), OCD (1)

This table also includes the patients' previous stressful life events. To this end, we used the Amiel Lebigre \[[@CR26]\] questionnaire, which, according to the author, is constructed from previous life event scales \[[@CR27], [@CR28]\]. Patients were asked to rate from 1 to 100 the impact of 52 precise stressful life events (+one open) on their lives. The authors consider that a global score greater than 200 is suggestive of depression. For the study, the interviewers asked the patients to focus on the period during which the headache became chronic.

Finally, we considered the pain intensity factor associated with the headache, which, a priori, is lower in patients with tension-type headache (level light or moderate, IHS criteria 2.1.C), in contrast to patients with migraine headache (level moderate or severe criteria 1.1.C) is may be used for inclusion. To this end, we established a pain index composed by the sum of the number of days with headache multiplied by a semi-quantitative evaluation of the pain intensity (0 to 3) during these days over last 3 months.

### Psychopathological and quality of life scales {#Sec6}

The tendency for depression was evaluated by using the Montgomery and Asberg Depression Scale (MADRS) \[[@CR29]\], a commonly used scale derived from the Comprehensive Psychiatric Rating Scale which contains 10 items (apparent and reported sadness, inner form, reduced sleep and appetite, concentration difficulties, lassitude, inability to feel, pessimistic, and suicidal thoughts) rated from 0 to 6. A total cut-off score of 15 may differentiate depressive subjects; a score of 20 is usually required for inclusion into therapeutic trials \[[@CR30]\].The severity of the anxiety symptoms was evaluated with the Hamilton anxiety scale HAMA (Hamilton anxiety) which consists in 14 items rated from 0 to 4: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic complaints, muscular or somatic complaints, sensory, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behaviour during the interview \[[@CR31]\]. A global score greater than 20 is usually required for inclusion into therapeutic trials. The authors consider two sub-scales: psychic anxiety (items 1--6 and 14) and somatic anxiety (items 7--13, underlined supra).Quality of life was evaluated by using the SF-36, a self-administered, 36-item questionnaire that measures health-related functions in eight domains : physical functioning (PF), role physical (RP), body pain (BP), general health perception (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH) \[[@CR32]\]; data from a control population, adjusted for gender and age, are reported in Table [3](#Tab3){ref-type="table"} \[[@CR33]\]. These domains are summarised by the mental component summary (MCS) and the physical component summary (PCS) which are loaded differently from the height domain sub-scores; the score of these mental and physical component summaries is about 50 \[[@CR34]\] in a control population*.*

Statistical methods {#Sec7}
-------------------

To limit the number of comparisons, we selected five variables which are widely used in the literature: the MADRS global score, the two HAMA sub-scales (HAMA psy, HAMA phy), and the two SF 36 dimension MCS and PCS.

Due to the different number of patients in each sub-groups, we carefully pooled our study patients in two different groups according to the clinical type of headache i.e. patients with migraine symptoms versus patients with tension-type symptoms by pooling CM and mMOH patients into a migraine group (*n* = 51) and CTT and ttMOH patients into a tension-type group (*n* = 55). To exclude pain intensity, which is a predicted confusion-factor, we used an ANCOVA to control the pain index, after testing for the non-heterogeneity of the variance with a Levene's test. When significant differences were present, we performed further explanatory comparisons using the same methodology.

Results (Tables [1](#Tab1){ref-type="table"} and [2](#Tab3){ref-type="table"}) {#Sec8}
==============================================================================

The MARDS mean global score was less than 20 in each of the four sub-groups and did not differ significantly between the migraine and tension-type groups (see details in Table [2](#Tab2){ref-type="table"}).Table 2Data of MADRS, HAMA and SF36 subscales in the 4 sub-groupsSub-group 1\
Chronic migraine\
8Sub-group 2\
Medication overuse headache migraine type\
43Sub-group 3\
Chronic tension type headache\
18Sub-group 4\
Medication overuse headache tension type\
37Comparison: migraine group (1 + 2) versus tension type group (3 + 4)\
*F*(1,103)MADRS global score17 ± 7.012.6 ± 10.09.2 ± 9.711.1 ± 7.80.947\
nsHAMA psychological anxiety11.8 ± 4.88.2 ± 56.2 ± 4.87.5 ± 4.91.498\
nsHAMA somatic anxiety9.8 ± 4.58.3 ± 4.47.6 ± 4.45.5 ± 3.510.10\
*p* = 0.001SF 36 physical component summary40.8 ± 7.644.8 ± 7.944.8 ± 7.044.9 ± 6.30.027\
nsSF 36 mental component summary31.4 ± 8.335.5 ± 11.141.8 ± 10.841.3 ± 11.85.758\
*p* = 0.018

The HAMA mean global score was high in CM (21.6 ± 9.0) and remained below 20 in CTTH (15.6 ± 9.7), mMOH (16.3 ± 8.5), and in ttMOH (12.4 ± 7.5) subgroups. The HAMA psychological and somatic sub-scores are reported in Table [2](#Tab2){ref-type="table"}. These sub-scores were constantly higher in CM and mMOH than in CTTH and ttMOH sub-groups. However, the statistical comparison between the migraine and tension-type groups showed a significant difference only for the somatic HAMA subscale (*p* = 0.001 see Table [2](#Tab2){ref-type="table"}).

The SF 36 physical and mental component summary scores are reported in Table [2](#Tab2){ref-type="table"}. Scores were always lower (therefore the patients were more disabled) in the CM sub-group and all the scores were lower than the scores seen in the general population (which is about 50): comparison between migraine and tension-type groups revealed that the mental component summary was lower in the migraine group (*p* = 0.018 see Table [2](#Tab2){ref-type="table"}).

To explain these differences, we considered the eight SF36 domain scores according to clinical sub-groups (see Table [3](#Tab3){ref-type="table"}). With the exception of physical functioning, sub-scale scores were often 20 points lower than control scores and were constantly lower in the CM sub-group. However, comparison between tension-type and migraine groups only revealed significant differences in two domains, which were lower in the migraine group: mental health (MH, *p* = 0.005) and bodily pain (BP, *p* = 0.036)Table 3SF 36 sub-scales in the four sub-groups and historical controls m (SD)Historical controlsSub-group 1\
Chronic migraineSub-group 2\
Chronic tension type headacheSub-group 3 mMOHSub-group 4 ttMOHComparison: migraine type (1 + 3) versus tension type (2 + 4) *F*(1,103)Physical functioning91.670.0 (24.6)84.2 (21.9)79.5 (22.0)83.5 (12.0)1.25 nsRole limitation physical87.931.2 (29.1)58.33 (7.4)49.4 (42.4)56.9 (34.1)0.39 nsBodily pain83.830.3 (10.3)47.1 (12.1)39.1 (16.7)48.9 (18)4.51 *p* = 0.036General health perception73.843.0 (14.2)49.8 (20.0)53.0 (19.6)54.5 (18.9)0.01 nsVitality61.934.3 (11.4)55.0 (18.7)41.3 (20.2)48.3 (18.8)2.92 nsSocial functioning89.451.6 (19.4)60.4 (30.1)53.8 (27.1)67.0 (26.1)2.42 nsRole limitation emotional84.341.7 (34.5)61.1 (40.0)47.3 (41.9)64.8 (37.0)3.04 nsMental health7431.0 (10.8)58.9 (15.7)47.5 (16.6)56.4 (18.4)8.17 *p* = 0.005

Discussion {#Sec9}
==========

Our data focus on the fact that, among patients who suffer from chronic daily headache, there is a difference between patients with migraine symptoms and those with tension-type headache symptoms. Our data indicate that the tendency towards anxiety, already reported in chronic daily headache, is mostly manifested by the somatic symptoms reported by patients with migraine symptoms whether or not they are drug-abusers. Indeed, the HAMA somatic sub-scale, which is significantly different in patients with and without migraine symptoms, is composed of seven items related to somatic symptoms (two general somatic, one cardiovascular, one respiratory, one gastro-intestinal, one sexual and urinary, and one autonomic). This propensity for headache patients to express somatic symptoms had been already reported with other psychological tools \[[@CR35], [@CR36]\]; our data suggest that in the whole group of CDH, the anxiety increase is rather due to the somatic anxiety of the patients with migraine symptoms. This raises the following questions: do migraine symptoms have a particular propensity to induce somatic anxiety, or does somatic anxiety increase the occurrence of a migraine symptoms? Interestingly our data do not suggest a high level of somatic and psychological anxiety in the two subgroups with medication overuse (see Table [2](#Tab2){ref-type="table"}), which lead to discuss two hypothesis: either a special trait of MOH patients or, an anxiolytic effect of the drug abuse itself.

The raw SF 36 height domain data suggest that all categories of chronic daily headache patients have an excessively low quality of life. In our cohort as well as in others' \[[@CR17], [@CR37]\], all domains of the SF 36 except one (physical functioning) were significantly affected in the four groups of patients; in addition, the mean scores were often 20 to 40 points different from the scores in historical controls (Table [3](#Tab3){ref-type="table"}). It is not surprising that the Physical Functioning score, which is the result of 10 questions mainly concerned with purely motor performances, is the least-affected domain. Our data strongly suggest a high burden since in this test, a five point difference is considered clinically or socially relevant \[[@CR38]\]. The control group is based on data obtained from the Oxford Healthy Life Survey (13,042 subjects between 18 and 64 years old, response rate 72% (see details in Ref. \[[@CR34]\]). We adjusted the normative data for gender and age in our study. The severity of the quality of life impairment is also suggested by the historical comparison of SF 36 performed in epileptic patients who reported more than one seizure per month \[[@CR39]\] and who seemed to be less affected in all domains.

When considering the impairment in global quality of life, the SF36 mental domain and more precisely, the mental health and the bodily pain dimensions are significantly more impaired in patients with migraine symptoms than in those with tension-type symptoms. Bodily Pain may be considered to represent a measure of the discomfort induced by repeated pain and Mental Health as the inability to feel that one has a healthy psychic functioning. These data are worth considering since the factor intensity of pain is supposedly neutralised by the statistical procedure. One interpretation could be that, confronted with a pain of equivalent intensity, migraine patients are particularly vulnerable as compared to tension-type patients. If we integrate our data with the biological--psychological--social framework of headache as developed by Nicholson et al. \[[@CR40]\], we can also hypothesise that among chronic daily headache patients, those with migraine symptoms may have either a greater predisposition to developing negative pain-related affects, or an higher vulnerability to quality of life discomfort.

Some aspects of our study deserve confirmation in future studies. Previous stressful life events may be more prevalent in CM patients and may deserve to be specifically studied. Previous psychiatric disorders need to be analysed with a systematic and comprehensive tool. The depressive tendency of our patients, evaluated by the mean MADRS score, did not reach a level usually considered to represent overt pathology \[[@CR41]\] in each sub-groups. This data differ from Mitsikostas and Thomas findings \[[@CR13]\]; they compared several headache sufferer subsets and found that the "drug abuse headache group" had the highest mean score in the Hamilton Depression Scale and even reached a pathological level. This point is important if we consider that some previously cited reports showed an increase in mood disorders in CDH \[[@CR10], [@CR11], [@CR14]\]. The level of medication overuse may account for part of these apparent discrepancies: the patients of our group were included according to the most recent ICHD 2004/2006(code 8.2) definition, which requires a regular intake of opiates alone or in combination for 10 days/month or more and for 15 days/month or more when other analgesics are taken. The patients in the previous cohorts had a more frequent medication intake since they were recruited either according to the 1988 IHS classification (code 8.2-4) \[[@CR42]\] in which daily analgesic use is mandatory or when they took drugs for 18 days/month or more \[[@CR15]\]. It seems likely that when drug abuse is greater, the mean depressive level is higher.

Our study is limited by some methodological drawbacks which need to be discussed. Our selected and heterogeneous cohort can hardly be considered to represent CDH in the general population, but we may hypothesise that the psychopathological problems reported by patients in our study cohort somewhat reflect the psychopathological problems seen in CDH patients in general, whatever the mode of selection. Selecting purely CM patients is difficult since they often abuse medication; specific studies are needed in this sub-group since their scores were highly pathological if we consider the scores they obtained in all the evaluation scales. The use of spontaneous patient recall, which induces an obvious bias in historical items and the number of days with a given type of headache combined with the small size of the CM group, suggests that this study needs to be repeated with a larger patient cohort and the use of a diary before inclusion. The overlap of a limited number of patients does not invalidate our study although it does reduce the strength of the analysis.

This study was sponsored by Astra Zeneca France.
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